Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Prolongs OS Among Patients with Early-Stage TNBC By Ogkologos - November 8, 2024 703 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-522 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer... February 23, 2023 Anal Cancer Advances Open Door to Screening and Prevention June 7, 2024 Patients Diagnosed with Cancer During Pregnancy May Have Increased Risk of... April 27, 2023 Hamlet Drug, Modeled After Protein In Breast Milk, Kills Tumor Cells... June 26, 2019 Load more HOT NEWS Should alcohol marketing be dropped from televised sport? PICOS Score May Help in Identification of Patients with Brain Metastasis... Our sun safety messaging tours the UK with the NIVEA Sun... Research with integrity – referencing work is way more than just...
